"Harnessing the power of the adaptive and innate immune systems"
At a glance
Tusk Therapeutics is a privately-held, immuno-oncology company, focused on discovering and developing unique therapeutic antibodies that harness the power of the immune system for the treatment of cancer.
The Company has established a growing, diversified pipeline of antibodies against a selection of both novel and validated targets that play an important role in the immune response to cancer. The Company’s programmes target the tumour microenvironment and exert their action through modulation, activation and/ or depletion of these immune cells.
Tusk has a world-class leadership team as well as outstanding scientific advisors, including top immuno oncology researchers, and the team has extensive biotech and pharma experience in antibody discovery and drug development, with a track record of bringing drugs from early stage discovery through to approval.
The Company is based at the Stevenage Bioscience Catalyst in Stevenage UK.
Developing novel immune modulating cancer therapeutics based on an in-depth understanding of the innate and adaptive immune system
Scientific Advisory Board
Products & Pipeline
CD25 is a Treg depleting agent in-licensed from UCL & CRUK. CD25 has shown convincing pre-clinical in vivo proof of concept data, both as a monotherapy and in combination with PD-1 and PDL-1.
CD38 is a novel immune checkpoint and is being considered as an important backbone of future immuno-oncology therapies next to the current PD1/PDL1 products on the market. Initial applications have been developed very successfully for multiple myeloma, and Tusk’s focus is on broadening the target's application into solid tumor indications.
Tusk is validating novel targets in the immuno-oncology space.
Partners & Collaborators
News & Events
Tusk Therapeutics presents data on to its anti-CD25 programme at AACR Annual Meeting 201818 April 2018
Tusk Therapeutics to Present Data at AACR Annual Meeting 201828 March 2018
BioCentury article: CD38 Hat Trick21 December 2017
Tusk Therapeutics awarded £2.5 million Grant from Innovate UK’s “Biomedical Catalyst Round 2 Late Stage”14 November 2017
To discuss potential collaborations with Tusk Therapeutics, or to arrange a meeting at any of the conferences listed below, please contact our business development team.
- Keystone: Cancer Immunotherapy Combinations - 14-18 April 2018 - Chicago
- AACR Annual Meeting - 14-16 April 2018 - Chicago
- BioEquity Europe - 14-16 May 2018 - Ghent
- Biotech Investment Showcase - 22-23 May 2018 - London
- BIO International Convention - 4-7 June 2018 - Boston
- CRI-CIMT-EATI- AAC Conference on Immunotherapy - 30 Sept - 3 Oct 2018 - New York
- BIO Europe - 5-7 Nov 2018 - Copenhagen
- SITC - 7-11 Nov 2018 - Washington
- PEGS Europe - 12-18 Nov 2018 - Lisbon
- EORTC-NCI-AACR 13-16 Nov 2018- Dublin